We Understand the Value of Strong Collaborations
Our Industry Collaborators
- Sumitomo Dainippon Pharma
- Roivant Sciences
- Enyo Pharma
We have a strategic development and commercialization agreement with Sumitomo Dainippon Pharma for the development and commercialization of Imeglimin in Japan, China and 11 other Asian countries. For Japan, we are jointly conducting the Phase 3 TIMES program for the treatment of type 2 diabetes and Sumitomo Dainippon Pharma will commercialize Imeglimin for this market. In China, South Korea, Taiwan and nine other Southeast Asian countries including Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos, Sumitomo Dainippon Pharma will be solely responsible for the development and commercialization of Imeglimin.
We have a strategic development and license agreement with Roivant Sciences for Imeglimin in the U.S., Europe, and other countries worldwide that are not covered under the Sumitomo Dainippon Pharma agreement.
We have a licensing agreement with Enyo Pharma for our FXR (farnesoid X receptor) agonist. Enyo has advanced this program into a Phase 1 study for Hepatitis B and plans to study NASH.
Our Academic Collaborators
- CarMeN Laboratoire de recherche Cardiovasculaire, Métabolisme, Diabétologie et Nutrition, Université Lyon UMR INSERM 1060, France
- INSA Lyon, Hospices Civils
- Kobe University, Japan
- Université de Grenoble U1042 & UMR_S 1055, France
- Université de Rouen UMR INSERM 1096, France
- Yale University, New Haven, CT, USA
We collaborate on an ongoing basis with academic leaders in metabolic disease, cardiovascular disease and mitochondrial dysfunction.
Interested in Collaborating with Us?
We'd love to hear from you and discuss partnership opportunities.